Eupraxia Pharmaceuticals Statistics

Total Valuation

Eupraxia Pharmaceuticals has a market cap or net worth of CAD 179.18 million. The enterprise value is 165.52 million.

Market Cap	179.18M
Enterprise Value	165.52M

Important Dates

The last earnings date was Friday, November 8, 2024.

Earnings Date	Nov 8, 2024
Ex-Dividend Date	n/a

Share Statistics

Eupraxia Pharmaceuticals has 35.62 million shares outstanding. The number of shares has increased by 40.29% in one year.

Current Share Class	n/a
Shares Outstanding	35.62M
Shares Change (YoY)	+40.29%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	20.39%
Owned by Institutions (%)	5.24%
Float	25.57M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	13.93
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-4.34
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-4.08

Financial Position

The company has a current ratio of 4.17, with a Debt / Equity ratio of 0.01.

Current Ratio	4.17
Quick Ratio	3.70
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	-0.00
Interest Coverage	-36.63

Financial Efficiency

Return on equity (ROE) is -301.58% and return on invested capital (ROIC) is -128.67%.

Return on Equity (ROE)	-301.58%
Return on Assets (ROA)	-110.11%
Return on Capital (ROIC)	-128.67%
Revenue Per Employee	n/a
Profits Per Employee	-1.31M
Employee Count	29
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -21.41% in the last 52 weeks. The beta is 1.23, so Eupraxia Pharmaceuticals's price volatility has been higher than the market average.

Beta (5Y)	1.23
52-Week Price Change	-21.41%
50-Day Moving Average	3.74
200-Day Moving Average	4.10
Relative Strength Index (RSI)	71.03
Average Volume (20 Days)	59,737

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-42.56M
Pretax Income	-38.88M
Net Income	-38.12M
EBITDA	-42.41M
EBIT	-42.56M
Earnings Per Share (EPS)	-1.20

Full Income Statement

Balance Sheet

The company has 11.70 million in cash and 125,705 in debt, giving a net cash position of 11.58 million or 0.32 per share.

Cash & Cash Equivalents	11.70M
Total Debt	125,705
Net Cash	11.58M
Net Cash Per Share	0.32
Equity (Book Value)	10.78M
Book Value Per Share	0.36
Working Capital	10.16M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -40.42 million and capital expenditures -147,655, giving a free cash flow of -40.57 million.

Operating Cash Flow	-40.42M
Capital Expenditures	-147,655
Free Cash Flow	-40.57M
FCF Per Share	-1.14

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Eupraxia Pharmaceuticals does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-40.29%
Shareholder Yield	-40.29%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a